盐酸缬更昔洛韦片的使用说明

Cytomegalovirus infection is a common complication after organ transplantation, with an incidence rate as high as 50%. The pain caused by organ rejection, cardiovascular disease, post-transplantation diabetes and related treatments seriously affects the quality of life of patients. It is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. It can effectively prevent and treat cytomegalovirus infection through correct oral administration every day, and significantly improve the patient's quality of life and long-term survival rate.

Valganciclovir Hydrochloride Tablets are suitable for the prevention of cytomegalovirus (CMV) in high-risk adult kidney, heart, and pancreas transplant patients (donor CMV seropositive/recipient CMV seronegative). Prevention of cytomegalovirus (CMV) in high-risk children with kidney transplantation (4 months to 16 years old) and heart transplantation (1 month to 16 years old). Cytomegalovirus Retinitis, Treatment (AIDS-Related): Treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).

Adult patients should use valganciclovir hydrochloride tablets rather than Vancevir oral solution. Oral solutions and tablets should be taken with food. Valganciclovir hydrochloride tablets should not be broken or crushed. Before dispensing the medication to the patient, the pharmacist must prepare an oral solution (50 mg/ml) with valganciclovir hydrochloride.

Recommended dose in adults with normal renal function, treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

Prophylaxis of Cytomegalovirus (CMV) in Pediatric Renal Transplant Patients: For pediatric renal transplant patients 4 months to 16 years of age, the recommended once-daily mg dose (7 × BSA (bovine serum albumin) × CrCl (creatinine clearance)) should be initiated within 10 days after transplantation and continued until 200 days after transplantation.

Cytomegalovirus prophylaxis: For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg orally once daily starting within 10 days of transplantation and continuing until 100 days after transplantation. For adult patients who have received a kidney transplant, the recommended dose is 900 mg taken orally once daily starting within 10 days after transplantation and until 200 days after transplantation.